ESTA Signals Growth Mojo as Q2 2026 Revenue Climbs and Guidance Bends Higher

The NASDAQ ticker ESTA and Establishment Labs touched a reassuring chord in Q2 2026, delivering a revenue beat that stacks up against last year’s base and lifting full-year revenue guidance. The company reported Total revenue of $67.5 million for the quarter ended June 30, 2026, up 31.7% from the year-ago period, with Motiva USA revenue alone rising to $24.7 million from $10.3 million a year prior. The tone is one of existing growth drivers extending into 2027, a narrative the firm echoed in its commentary and margins data.

On the margin line, gross profit reached $47.7 million, or 70.6% of revenue, a modest margin expansion versus the year-ago period. The company attributes the improvement to favorable geographic and channel mix, including continued strength in the higher-margin U.S. business and the expansion of its minimally invasive platform.

Quarterly snapshot

Revenue: $67.5 million; YoY growth 31.7%
Gross margin: 70.6% (gross profit $47.7 million)
Operating loss: $4.3 million (vs. $14.1 million loss year-ago)
Adjusted EBITDA: $3.7 million in income (vs. $8.5 million loss year-ago)
Cash and equivalents: $71.2 million as of June 30, 2026; up $3.1 million from Q1 2026
U.S. revenue: $24.7 million (up from $10.3 million in the prior-year period)

Outlook and management tone

Management raised its full-year revenue guidance to a range of $269 million to $271 million, signaling confidence in second-half execution and continued growth from the minimally invasive platform. The message is purposefully forward-looking: momentum is expected to persist into the second half of 2026 and into 2027, with profitability anticipated to remain on an improving trajectory.

“Momentum continued throughout the second quarter and into the third quarter as we continue to take market share and expand the category,” said Peter Caldini, Chief Executive Officer. “Strong execution globally, accelerating adoption of our minimally invasive platform, and expanding profitability allows us to raise our full-year revenue guidance. We should have strong growth in the second half of 2026 and throughout 2027, as our business inflects to be both high growth and free cash flow positive.”

Implications for ESTA and sector peers

The numbers underscore a couple of durable themes: a higher-margin U.S. business, a mid-teens to high-singles lift in top-line growth, and a cash cushion that supports ongoing investments rather than distress-driven cost cuts. In a sector where cosmetic and minimally invasive devices often hinge on reimbursement cycles, product acceptance, and the pace of geographic expansion, Establishment Labs’ Q2 cadence supports a thesis that the category remains dynamic but increasingly efficiency-driven.

The EPS conversation—earnings per share in the GAAP sense or the non-GAAP flavor investors often care about—remains a dialog for later quarters, given the current release focuses on revenue, gross margin, and EBITDA-like metrics. Investors watching for an earnings surprise or an EPS consensus figure should note that the company did not present formal EPS data in this release; future results will need to translate this top-line strength into per-share profitability signals to satisfy broader analyst expectations.

What to monitor going forward

Key data points that could tilt sentiment include: whether the revenue forecast proves robust across the back-half plan, any shifts in the margin mix as foreign operations scale, and the trajectory of adjusted EBITDA and free cash flow in the second half of 2026. As ESTA statements begin to include EPS commentary or disclosures around working capital, investors will look for a concrete EPS consensus path and any earnings surprise relative to Street expectations.

Sector peers—particularly companies leaning into minimally invasive platforms and medical aesthetics—will be keen to compare their own margin evolution and domestic vs. international mix to ESTA’s progress. A credible step function in profitability, if sustained, could pressure peers to accelerate cost discipline while preserving top-line growth.

Bottom line

Establishment Labs’ Q2 2026 update provides a coherent narrative: revenue growth accelerating, a healthier gross margin, and an upgraded annual revenue forecast that paints a picture of a company turning volume into value. The lack of an explicit EPS figure in this release shouldn’t be mistaken for a lack of momentum—the cash balance remains ample, and management’s outlook hinges on continued execution and expanding market share. For ESTA, the story now hinges on translating top-line strength into sustainable profitability and translating that profitability into a credible EPS path that can satisfy EPS consensus expectations and any potential earnings surprise from the street.